Revolutionizing Medical AI Development: Flywheel Announces $54 Million in Series D Funding led by Novalis LifeSciences and NVentures
Flywheel, the leading medical imaging data and AI platform, announces it has raised $54 million in Series D funding with more to come soon. This latest round of funding was co-led by Novalis LifeSciences LLC and NVentures, NVIDIA’s venture capital arm. Microsoft also participated in the round, along with insiders Invenshure, 8VC, Beringea, Hewlett Packard Enterprise, Intuitive Ventures, iSelect, Gundersen Health System, Seraph, and Great North Ventures. Faegre Drinker Biddle & Reath LLP served as counsel to Flywheel in connection with the financing.
“Flywheel’s products transform healthcare innovation by empoweri...
Source: EMR and HIPAA - July 20, 2023 Category: Information Technology Authors: Healthcare IT News Tags: Health IT Company Healthcare IT 8VC Beringea Faegre Drinker Biddle & Reath LLP Flywheel Great North Ventures Gundersen Health System Health IT Funding Health IT Fundings Health IT Investment Hewlett Packard Enterprise Intuitive Ven Source Type: blogs
Opinion Piece from Pharmacists United for Truth & Transparency ( " PUTT " )
Pharmacists United for Truth& Transparency ( " PUTT " ) is a non-profit advocacy organization founded by independent pharmacists and pharmacy owners devoted to exposing what they describe as anti-competitive tactics deployed by the largest Pharmacy Benefit Managers (PBMs - aka Pharmacy Benefit Companies or PBCs as the trade organization known as the Pharmaceutical Care Management Association or PCMA has tried to rebrand its industry since the acronym PBM has become toxic) recently published an opinion piece with an interesting title: " The Deadliest Addiction in the U.S. Isn ' t What You Think It Is " (read it athttps:...
Source: Scott's Web Log - July 12, 2023 Category: Endocrinology Tags: 2023 drug prices PBM Pharmacists United for Truth & Transparency PUTT Source Type: blogs
Ending the opioid crisis starts with physicians
A recently published opinion article by opioid advocates attempts to assuage physicians’ prescribing guilt, arguing “doctors prescribing to their patients did not create the U.S. opioid crisis.” As lawsuit after lawsuit concludes, Purdue Pharma, Johnson and Johnson, and blindered distributors and pharmacies share the blame for propping up pills for profit. Physicians may inflate home narcotic
Read more…
Ending the opioid crisis starts with physicians originally appeared in KevinMD.com. (Source: Kevin, M.D. - Medical Weblog)
Source: Kevin, M.D. - Medical Weblog - July 11, 2023 Category: General Medicine Authors: Amy Baxter, MD Tags: Conditions Pain Management Source Type: blogs
Fight Aging! Newsletter, July 10th 2023
In conclusion, the examination of the GBA can aid in understanding the etiology and development of NDs, which may benefit the improvement of clinical treatments for these disorders and ND interventions. This review indicates existing knowledge about the involvement of microbiota present in the gut in NDs and potential treatment options.
The Aging of the Enteric Nervous System
https://www.fightaging.org/archives/2023/07/the-aging-of-the-enteric-nervous-system/
The enteric nervous system is the nervous system of the intestines, and likely an important part of the relationship between the gut microbiome ...
Source: Fight Aging! - July 9, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Progress Towards Rejuvenation as a Matter of Investment versus a Matter of Time
It is not hard to argue that there is too little investment in progress towards the treatment of aging as a medical condition. Collectively, the underlying mechanisms of degenerative aging are the cause of two-thirds of human mortality, and likely a somewhat greater fraction of loss of function, suffering, and pain. The cost of that mortality is vast, no matter how one likes to model the value of a human life, or a year spent alive in good health. This is much the same argument that can be made for greater investment in medical research in general. Medical research funding as a whole is a very, very tiny fraction of the co...
Source: Fight Aging! - July 4, 2023 Category: Research Authors: Reason Tags: Healthy Life Extension Community Source Type: blogs
The Business Reality of Healthcare AI
BY KIM BELLARD
I was at the barbershop the other day and overheard one barber talking with his senior citizen customer about when – not if – robot AIs would become barbers. I kid you not.
Now, I don’t usually expect to heard conversations about technology at the barber, but it illustrates that I think we are at the point with AI that we were with the Internet in the late ‘90’s/early ‘00s: people’s lives were just starting to change because of it, new companies were jumping in with ideas about how to use it, and existing companies knew they were going to have to figure out ways to incorporate it if they ...
Source: The Health Care Blog - July 4, 2023 Category: Consumer Health News Authors: Ryan Bose-Roy Tags: Health Tech Healthcare AI healthcare delivery Kim Bellard Source Type: blogs
Drugs Vs. Digital Therapeutics – A Digital Symbiosis
In conclusion, it’s not about Drugs vs DTx. It’s about Drugs & DTx, leveraging the strengths of both for maximal benefits.
The post Drugs Vs. Digital Therapeutics – A Digital Symbiosis appeared first on The Medical Futurist. (Source: The Medical Futurist)
Source: The Medical Futurist - July 4, 2023 Category: Information Technology Authors: Andrea Koncz Tags: E-Patients Future of Pharma Personalized Medicine Telemedicine & Smartphones DTx digital therapeutics prescription apps Source Type: blogs
Apixio and ClaimLogiq Merge to Create a Leading Connected Care Platform
New Mountain Capital Leads Follow-On Investment to Enable the Merger
Eir Partners Provides Additional Capital to Support the Transaction
Apixio, an artificial intelligence company that supports health plans and provider groups in their delivery of value-based care, announced today that it has completed its merger with ClaimLogiq, a healthcare technology business that delivers savings for health plans by reducing claim errors prior to payment. Together, the combined entity will be branded as Apixio.
The merger creates a leading healthcare data and analytics company powered by an advanced AI-driven platform that applies both...
Source: EMR and HIPAA - June 30, 2023 Category: Information Technology Authors: Healthcare IT News Tags: Health IT Company Healthcare IT AI Apixio Brett Carlson ClaimLogiq Eir Partners Health IT Acquisitions Healthcare Data Healthcare M&A J.P. Morgan Securities LLC Matt Holt New Mountain New Mountain Capital Ropes & Gray LLP Sac Source Type: blogs
Like Don Quixote Chasing Windmills, I Aim to See Financial Remediation for Patients Still Suffering in a Predatory U.S Healthcare System
Sometimes, I feel (if you pardon the metaphor) a bit like Don Quixote chasing windmills with my efforts to see true financial remediation introduced in the predatory U.S. healthcare " system " (and I am glad to see that the term " predatory " is now being used by a growing number of medical doctors, which I think is great). I envision a type of financial remediation whereby patients will be able to get access to the care they need without having to face financial predators trying to pick their pockets with illegal discount bribes standing in the way of their getting access to things they need like insulin, CGM senors ...
Source: Scott's Web Log - June 25, 2023 Category: Endocrinology Tags: 2023 CGM Formulary Exclusion insulin PBM Source Type: blogs
RxLightning Closes $17.5M Series A to Accelerate Growth and Remove Barriers to Essential Specialty Medications
LRVHealth, McKesson Ventures, Novartis, Hearst Ventures, Onco360, and HealthX Ventures Join Investment Round to Redefine Specialty Patient Access and Onboarding
RxLightning, creator of the industry’s first comprehensive platform for streamlining specialty medication access and affordability, today announced that it closed a $17.5 million Series A investment to support the company’s growth and further remove barriers to life-saving therapies. The round was led by LRVHealth, with participation from McKesson Ventures and existing investors Novartis (dRx Capital), Onco360 (BrightSpring Health Services), Hearst Ventures, an...
Source: EMR and HIPAA - June 19, 2023 Category: Information Technology Authors: Healthcare IT News Tags: Health IT Company Healthcare IT BrightSpring Health Services Carrie Williams dRx Capital EHR FDA Health IT Funding Health IT Fundings Health IT Investment HealthX Ventures Hearst Ventures Josh Flum Julia Regan LRVHealth McKes Source Type: blogs
What happens when Rx price bubbles (such as on insulin) burst?
In the first half of 2023, Americans witnessed evidence of a rather fundamental shift in the manner pharma had traditionally opted to commercialize selected prescription drugs. Specifically, in March 2023,Lilly,Novo Nordisk andSanofi each announced they planned to slash insulin list prices for insulin. To do so, they would disintermediate PBMs from the transaction and " opt out " of the PBM commercialization channel.The decision wasn ' t really all that difficult; for years branded insulin-makers had been complaining that PBMs and other drug distribution system entities had been gobbling up an ever-larger share of their re...
Source: Scott's Web Log - June 19, 2023 Category: Endocrinology Tags: 2023 Source Type: blogs
Fight Aging! Newsletter, June 19th 2023
In conclusion, among Swedish middle-aged subjects, nearly two-thirds showed complete fatty degeneration of thymus on CT.
Age-Related Dysfunction of Water Homeostasis
https://www.fightaging.org/archives/2023/06/age-related-dysfunction-of-water-homeostasis/
Dehydration can be an issue in older people. As in every complex system in the body, the mechanisms by which hydration is regulated become dysfunctional with advancing age. Researchers here look at the brain region responsible for regulating some of the response to dehydration, cataloging altered gene expression in search of the more important mechan...
Source: Fight Aging! - June 18, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Notes from the 2023 Age-Related Disease Therapeutics Summit
The former Longevity Therapeutics conference series was renamed to the Age-Related Disease Therapeutics Summit and held its fifth event recently in San Francisco. It was a smaller meeting than in past years, perhaps a result of the recent downturn in the global financial and investment environment. Few investors were present. Nonetheless, one can usually learn something interesting from the presenting biotech founders and executives. I took a few notes while I was there to present on progress at Repair Biotechnologies, and they follow in the order of the conference program.
Birget Schilling from the Buck Institute f...
Source: Fight Aging! - June 16, 2023 Category: Research Authors: Reason Tags: Longevity Industry Source Type: blogs
Sandoz/Gan & Lee Now Has Applications for Glargine, Lispro and Aspart Insulin Biosimilars on File with FDA, Expect them to come to market in early 2024.
Five years ago, back on December 19, 2018, Swiss pharmaceutical giant Novartis Pharma AG quietly issued a press release (seehttps://www.globenewswire.com/news-release/2018/12/19/1669194/0/en/Sandoz-enters-into-commercialization-and-supply-agreement-for-insulin-biosimilars-anticipating-growing-demand-as-diabetes-burden-rises.html for the release itself) on behalf of the company ' s business unit known as Sandoz. Specifically, Novartis said that its Sandoz generics unit planned to introduce biosimilars, or near-copy, versions of Sanofi ' s Lantus (glargine), Novo Nordisk ' s Novolog (aspart), and Eli Lilly ' s Humalog (lispr...
Source: Scott's Web Log - June 16, 2023 Category: Endocrinology Tags: 2023 Biosimilar biosimilars Gan & Lee insulin Sandoz Source Type: blogs
Free Download of The Capitol Forum's Report: " Exclusive Drug Dealing: Anticompetitive Practices in the Pharmaceutical Supply Chain "
In 2020, I wrote a blog post entitled " It ' s the Rx rebates, stupid! " (seehttps://blog.sstrumello.com/2020/09/its-rx-rebates-stupid.html for the post) in which I revealed the reason everyone was overpaying for insulin was because of rebating paid by insulin-makers to secure PBM formulary placement. Novo Nordisk revealed to its investors that it was spending 74% of its gross U.S. sales in the form of legally-exempted rebate kickbacks paid to PBMs. The good news is thanks to a series of actions by a number of different parties, the insulin PBM rebate price bubble finally burst whenLilly, followed byNovo Nordisk and thenSa...
Source: Scott's Web Log - June 11, 2023 Category: Endocrinology Tags: 2023 Exclusive Drug Dealing: Anticompetitive Practices in the Pharmaceutical Supply Chain report The Capitol Forum Source Type: blogs
